Products
Host Cell Residue Detection
Process Impurity Assay
Advnetitious Agent/Microorganism Testing
Pyrogen / Endotoxin Detection
Genetic Stability
Cell Line Characterization
Viral Titer Assay
Detection Equipment
Biochemical Reagents
Mycoplasma Testing Solutions
Traditional Pharmacopoeial Methods & Rapid qPCR ： Ensuring Product Safety from Cell Banks to Final Drug Products.
Mycoplasma contamination is a critical quality attribute in biopharmaceutical manufacturing. Mycoplasmas are the smallest self-replicating prokaryotes, lacking a cell wall and capable of passing through 0.2 μm sterilizing-grade filters. In cell cultures, they remain undetected—causing no turbidity and invisible under standard light microscopy—yet they significantly alter cellular phenotype, metabolism, and growth, posing significant risks to product safety and efficacy.
Key Risk: Undetected Contamination — Passes through 0.2 μm filters, no turbidity, invisible under standard microscopy, leading to undetected contamination in cell banks and harvests.
Key Challenge: Regulatory Deficiencies— Failure to meet pharmacopoeial requirements for mycoplasma testing leads to rejection of BLA, MAA, or IND submissions.
| Regulatory Body | Requirement |
| FDA (U.S.) | NAT recognized as a validated alternative to compendial methods, with USP <77> (effective Oct 2026) establishing standalone NAT framework. |
| EMA (Europe) | Defines culture, indicator cell, and NAT methods. NAT can replace culture if LOD ≤ 10 CFU/mL. |
| NMPA (China) | Chapter 3301: Requires both culture method and indicator cell culture (DNA staining) for cell banks and viral seeds. qPCR permitted following full method validation. |
| PMDA(Japan) | Harmonized with EP/USP; NAT methods accepted for rapid mycoplasma detection. |
Direct Culture Method (Compendial Gold Standard)
Test samples are inoculated into specialized liquid and solid agar media, followed by a 28-day incubation period. Detection based on turbidity, color change, or colony morphology.
Highest regulatory acceptance
Detects viable contaminants
28-day incubation
Minimum total test article volume: 6 mL | TAT: 35 business days
Indicator Cell Assay with Fluorescent DNA Staining (For Fastidious Mycoplasmas)
Inoculation onto Vero or other indicator cells, incubation, then DNA-specific fluorescent staining. Mycoplasma colonies appear as fluorescent particles on cell surfaces.
Detects hard-to-culture species
Visual confirmation
~5-7 days + staining
Minimum sample volume: 2 mL | TAT: 35 business days
Rapid qPCR NAT (FDA DMF-Registered)
TaqMan probe-based real-time qPCR targets conserved 16S rRNA sequences across mollicutes. High sensitivity, wide species coverage, results in hours.
Sensitivity 10 CFU/mL (meets culture replacement)
~200 species coverage
Results in < 4 hours
Minimum sample volume: 2 mL | TAT: 10 business days
*TAT=Turnaround Time
*NAT=Nucleic Acid Amplification Test
Recommended Phase-Based Testing Strategy
Early-stage R&D: qPCR NAT for high-throughput rapid raw material and cell line screening
Clinical manufacturing: Combined compendial culture + indicator cell assay for batch release; qPCR for in-process rapid decision-making
Commercial supply: Fully validated compendial methods as primary release test; validated qPCR as complementary or alternative rapid release solution
| Core Advantage | Regulatory & Project Value for Your Team |
| Global Standard Lab Accreditations | ISO 13485:2016 certified; CNAS-accredited testing laboratory (CNAS: China National Accreditation Service for Conformity Assessment); enhanced BSL-2 facilities for secure handling of reference mollicute strains |
| Full 21 CFR Part 11 Data Integrity | End-to-end compliant electronic lab records, immutable audit trails and secure regulated data governance for FDA/EMA audit readiness |
| FDA DMF Registered qPCR Assay | MycoSHENTEK® qPCR detection kit holds FDA DMF No. MF29624; inter-laboratory validated with consistent 10 CFU/mL LOD across all common industrial mollicute species |
| Qualified Reference Strains | Authentic mycoplasma reference cultures sourced from global recognized culture depositories; propagated to exponential phase per EP 2.6.7 compendial specifications |
| Method | Minimum Sample Volume | Standard TAT | Key Regulatory Reference |
| Culture Method | 6 mL | 35 business days | ChP 3301, EP 2.6.7, USP <63> |
| Indicator Cell Culture (DNA Staining) | 2 mL | 35 business days | ChP 3301, EP 2.6.7 |
| qPCR (Real-time PCR) | 2 mL | 10 business days | EP 2.6.7, USP <63>, JP, FDA DMF |
Q: Is qPCR NAT fully accepted by global regulators for mycoplasma lot release?
A: qPCR NAT is recognized as a compendial alternative by USP <63>, EP 2.6.7, provided full method validation is completed to demonstrate equivalent or superior performance versus traditional culture assays. Regulators mandate an LOD ≤10 CFU/mL for full culture replacement, or ≤100 CFU/mL to substitute only the indicator cell assay. Our MycoSHENTEK® qPCR kit features FDA DMF registration MF29624 and inter-laboratory validation confirming a 10 CFU/mL limit of detection
Q: Which samples are mandatory for mycoplasma testing per global pharmacopoeia?
A: Regulators require mycoplasma screening across the full bioprocess chain: Master Cell Banks (MCB), Working Cell Banks (WCB), viral seed banks, control cell cultures, clinical-grade cell substrates, unprocessed production harvest fluids, and finished cell/gene therapy drug products. ChP 3301 and EP 2.6.7 require combined culture + indicator cell testing for initial cell bank qualification, unless a fully validated NAT is implemented as a formal replacement method.
Q: What is the difference between the culture method and indicator cell method?
A: The direct culture method uses specialized liquid and agar media to grow viable mycoplasmas over 28 days, detecting those that form colonies or cause media color change. The indicator cell culture (DNA staining) method is designed to detect fastidious mycoplasmas that are difficult to culture. It involves inoculating samples onto Vero or other indicator cells, followed by fluorescent DNA staining to visualize mycoplasma colonies attached to cell surfaces. Both are required by ChP and EP for cell bank release.
Q: Can I use qPCR for lot release testing instead of the 28-day culture?
A: Yes, after full validation demonstrating that the qPCR method meets compendial requirements (typically LOD ≤ 10 CFU/mL, specificity, robustness, and equivalency to culture methods). Many regulatory agencies now accept validated NAT methods as substitutes for traditional culture and indicator cell tests for routine lot release. However, for initial cell bank qualification, traditional methods are still strongly recommended or required. We can help design a validation bridging study.
Q: What minimum sample volume is required for each testing modality?
A: Per global pharmacopoeia specifications:
Direct culture method: minimum total test article volume of 6 mL
Indicator cell staining assay: minimum 2 mL
qPCR NAT assay: minimum 2 mL
For low-volume/limited clinical samples, contact our technical team to discuss customized concentration protocols.
Q: How to select a phase-aligned mycoplasma testing workflow for your product lifecycle?
A: We recommend a tiered, phase-appropriate testing strategy:
Early discovery & preclinical: Rapid qPCR NAT for cost-effective high-throughput raw material and cell line screening
Clinical trial manufacturing: Compendial culture + indicator cell assays for formal batch release; qPCR for urgent in-process screening
Commercial production: Compendial culture as primary release test; validated qPCR as a complementary or fully validated alternative release platform
Q: Are expedited testing timelines available?
A: Expedited mycoplasma testing workflows are offered for time-critical clinical and commercial manufacturing projects upon request.
EP 2.6.7: Mycoplasma
USP Chapter <63>: Mycoplasma Tests
ChP 2025 Chapter 3301: Mycoplasma Testing
FDA Guidance for Industry—Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications
返回
